Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13186255 | 0.86 | RAB9A (0.66) | KMT2AMEN1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL16656789 | 0.83 | SMN1; SMN2 (0.48) | KMT2AMEN1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL557468 | 0.82 | MAPT (0.45) | KMT2AMEN1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL12424048 | 0.82 | MEN1 (0.43) | KMT2AMEN1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL21652300 | 0.79 | KMT2A (0.65) | KMT2AMEN1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2202643 | 0.79 | CHRM3 (0.44) | KMT2AMEN1SMN1; SMN2GAAMAPT | |
| SCHEMBL2427404 | 0.77 | NTRK1 (0.44) | KMT2AMEN1SMN1; SMN2GAAMAPT | |
| SCHEMBL14564410 | 0.76 | MAPT (0.44) | KMT2AMEN1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL14564442 | 0.76 | MAPT (0.44) | KMT2AMEN1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL5165138 | 0.75 | CHRNA7 (0.47) | KMT2AMEN1SMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012360-B2 | Synergistic combinations of active ingredients | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-21 | — | — | US | disclosed |
| US-20120035050-A1 | Synergistic Combinations Of Active Ingredients | BAYER CROPSCIENCE AG (DE) | 2012-02-09 | — | — | US | disclosed |
| US-20110166109-A1 | Synergistic Active Compound Combinations Comprising Phenyltriazoles | BAYER CROPSCIENCE AG (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166109-A1 | Synergistic Active Compound Combinations Comprising Phenyltriazoles | BAYER CROPSCIENCE AG (DE) | 2011-07-07 | — | — | US | disclosed |
| WO-2011006603-A2 | SYNERGISTIC ACTIVE SUBSTANCE COMBINATIONS CONTAINING PHENYL TRIAZOLES | BAYER CROPSCIENCE AG (DE) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035050-A1 | Synergistic Combinations Of Active Ingredients | C1S, MAN2B1, MANBA | KMT2A 4084/4885MEN1 493/4885SMN1; SMN2 3057/4885 |
| US-20110166109-A1 | Synergistic Active Compound Combinations Comprising Phenyltriazoles | NAT1, ACAT1, CAT | KMT2A 1304/4885MEN1 2107/4885SMN1; SMN2 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.